Wall Street Zen Downgrades Aura Biosciences (NASDAQ:AURA) to Sell

Key Points

• Wall Street Zen downgraded Aura Biosciences from “hold” to “sell,” while broader analyst coverage remains mixed: two buys, one hold and one sell, with an average price target of $17.50.
• Aura reported a quarterly loss of $0.48 per share, missing the $0.38 consensus estimate, underscoring continued cash burn and the lack of near-term profitability.
• The stock opened at $7.69, well below the analyst average target, while institutional investors own 96.75% of shares; the company has also cut roughly 20% of its workforce to preserve cash for its late-stage eye-cancer trial.

Aura Biosciences (NASDAQ:AURA - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Sunday.

Other analysts have also recently issued research reports about the stock. Weiss Ratings raised shares of Aura Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, July 14th. Leerink Partners set a $17.00 target price on shares of Aura Biosciences in a research report on Tuesday, May 12th. Finally, HC Wainwright cut their price target on shares of Aura Biosciences from $24.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, August 11th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $17.50.

Aura Biosciences Price Performance

Shares of NASDAQ AURA opened at $7.69 on Friday. The business has a 50-day moving average of $7.02 and a two-hundred day moving average of $6.74. The company has a market capitalization of $797.53 million, a price-to-earnings ratio of -4.39 and a beta of 0.40. Aura Biosciences has a 1 year low of $4.73 and a 1 year high of $9.53.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.10). As a group, equities research analysts expect that Aura Biosciences will post -1.61 earnings per share for the current year.

Insider Activity

In related news, insider Anthony S. Gibney sold 12,824 shares of the business's stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $6.42, for a total value of $82,330.08. Following the transaction, the insider owned 265,354 shares in the company, valued at $1,703,572.68. The trade was a 4.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 1.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of AURA. BlackRock Inc. acquired a new stake in shares of Aura Biosciences during the second quarter worth $33,424,000. Vanguard Group Inc. increased its stake in shares of Aura Biosciences by 16.7% during the third quarter. Vanguard Group Inc. now owns 2,890,503 shares of the company's stock worth $17,863,000 after acquiring an additional 413,001 shares during the period. Jupiter Topco LLC purchased a new position in shares of Aura Biosciences during the 2nd quarter worth approximately $17,788,000. Nantahala Capital Management LLC boosted its stake in shares of Aura Biosciences by 67.1% in the second quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company's stock valued at $13,257,000 after buying an additional 850,000 shares in the last quarter. Finally, Trails Edge Capital Partners LP acquired a new position in Aura Biosciences during the second quarter worth $10,247,665,000. Institutional investors and hedge funds own 96.75% of the company's stock.

Aura Biosciences News Roundup

Here are the key news stories impacting Aura Biosciences this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and an $18 price target while raising its EPS forecasts for 2026 through 2030. The firm now expects narrower losses in the next several years and forecasts a return to profitability by 2030, when it projects $0.56 in EPS. Q1 Earnings Forecast for AURA Issued By HC Wainwright
• Positive Sentiment: Analyst sentiment remains broadly constructive toward Aura’s healthcare opportunity. Aura was included among healthcare stocks highlighted as having bullish analyst coverage, which may help offset concerns about its ongoing losses. Analysts Are Bullish on Top Healthcare Stocks
• Neutral Sentiment: Aura cut approximately 20% of its workforce to preserve cash and fund its late-stage eye-cancer trial. The move could extend the company’s runway, but it also highlights the financial demands and execution risks associated with advancing its clinical program. Aura Cuts 20% of Staff to Fund Late-Stage Trial
• Negative Sentiment: Aura reported quarterly EPS of negative $0.48, missing the negative $0.38 analyst consensus. The earnings shortfall triggered a gap-down move and reinforces concerns about the company’s continuing cash burn and lack of near-term profitability. Aura Biosciences Shares Gap Down Following Weak Earnings

Aura Biosciences Company Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source